Progyny (PGNY)
(Delayed Data from NSDQ)
$28.25 USD
-0.19 (-0.67%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $28.26 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.25 USD
-0.19 (-0.67%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $28.26 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays
by Zacks Equity Research
Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.
In Search of an Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases. Tap Yum China (YUMC), Impinj (PI), Five Below (FIVE), Hologic (HOLX) and Progyny (PGNY).
Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.
Encompass Health's (EHC) Plan Marks Entry in Rhode Island
by Zacks Equity Research
Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.
Here's Why Investors Should Retain Globus Medical (GMED) Stock
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.
UnitedHealth (UNH) Unit Ties Up to Boost Care in Two U.S. Regions
by Zacks Equity Research
UnitedHealth Group's (UNH) subsidiary Optum aims to advance organizational efficiencies of Owensboro Health and bring about better health outcomes in western Kentucky and southern Indiana.
Molina Healthcare (MOH) to Incur $200M Impairment Charge in Q4
by Zacks Equity Research
The reduction of Molina Healthcare's (MOH) real estate footprint is expected to result in a sizeable decline in leased real estate expense.
Humana (HUM) Subsidiary Wins $70.8B DoD East Region Contract
by Zacks Equity Research
The latest award marks Humana's (HUM) military subsidiary's sixth TRICARE contract win.
Here's What You Should Know From Centene's (CNC) 2023 Outlook
by Zacks Equity Research
Centene's (CNC) board boosts its share buyback program with a new $2-billion fund.
ELV vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Looking for Earnings Beat? Buy These 5 Stocks With Potential
by Sanghamitra Saha
These top-ranked stocks -- Chewy (CHWY), Progyny (PGNY), KnowBe4 (KNBE), Chegg (CHGG) and Fortinet (FTNT) -- are likely to beat on their bottom line in the next releases.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny
by Zacks Equity Research
Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and PGNY are set to gain the most. However, staffing shortages may disrupt the trend.
Cigna (CI) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Cigna's (CI) stock price is increasing on the back of solid performances in the Evernorth and Cigna Healthcare businesses.
ELV vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Wall Street Analysts See a 64% Upside in Progyny (PGNY): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 63.5% upside potential for Progyny (PGNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Progyny (PGNY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMN or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
MODV vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. PGNY: Which Stock Is the Better Value Option?
Does Progyny (PGNY) Have the Potential to Rally 64% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.5% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.